Contact Lanner

CONTACTER LANNER

Complete the form below for a quick response from a Lanner representative or call us on +44 (0)121 709 6520 or +1 713 532 8008. If you require support, please visit my.lanner.com

Remplissez le formulaire ci-dessous pour obtenir une réponse rapide d'un représentant Lanner ou appelez-nous au +33 1 87 16 90 15. Si vous avez besoin d'assistance, merci de vous connecter sur my.lanner.com

By submitting your personal details you are confirming agreement with our website terms of use, privacy policy and consent to cookies being stored on your device. En nous transmettant vos données personnelles, vous confirmez votre accord avec les termes d’utilisation de notre site internet et notre politique de confidentialité, et vous acceptez que des cookies soient stockés sur votre appareil.

Thank you for your enquiry.
A member of our team will be in touch as soon as possible.

  • By Tony Waller
  • In Blog
  • Posted 22/05/2013

Currently visiting WITNESS users around America, Tony Waller shares details of his visit to 3M in Minneapolis.

Last Friday was a great day in Minneapolis to visit a truly innovative company. 3M have been a byword for innovation since this principle was embedded in the organization by William McKnight in over 50 years of management and leadership of the company.

The technologies on display at their innovation centre were awe-inspiring, including micro-replication, nanotechnology and biotechnology.

For more click here.

One cornerstone technology that I was more than interested in was Predictive Engineering and Modeling. In this WITNESS simulation models were on display, highlighting the first class work that is done in this area at 3M by Dan Nottestad and Erin Murphy. Our meeting was to discuss new opportunities and explore the new experimenter being unleashed in WITNESS 13 but their past record with truly wide model applicability, experimental rigour and enthusiasm for simulation is a record of success.


Loading blog comments..

Post a Comment

Thank you, your comment is awating approval
Submit